A case–control study to predict the risk of gestational diabetes mellitus by initial fasting blood sugar or past gestational history by Ezazi Bojnordi, Tahmineh et al.
International Journal of Reproductive BioMedicine
Volume 19, Issue no. 4, https://doi.org/10.18502/ijrm.v19i4.9064
Production and Hosting by Knowledge E
Original Article
A case–control study to predict the risk of
gestational diabetes mellitus by initial fasting
blood sugar or past gestational history
Tahmineh Ezazi Bojnordi1 M.D., Sedigheh Hantoushzadeh2 M.D., Masomeh
Sabzevary2 M.D., Zahra Heidari3 Ph.D.
1Department of Obstetrics and Gynecology, Loghman Hospital, Shahid Beheshti University of
Medical Sciences, Tehran, Iran.
2Department of Gynecology and Obstetrics, School of Medicine, Tehran University of Medical
Sciences, Tehran, Iran.
3Department of Histology, Genetic of Non-communicable Diseases Research Center, Faculty of
Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Abstract
Background: Gestational diabetes mellitus (GDM) deserves proper prevention,
diagnosis, and management due to healthcare implications from both maternal and
fetal concerns.
Objective: To evaluate the rate and investigate the risk factors for developing GDM.
Materials and Methods: In this case-control, universal screening for GDM between 24
and 28 wk of gestation was performed in 613 pregnant women attending a prenatal
clinic in Tehran who were followed-up until delivery between March 2017 to March
2018. Of the 613 women, 143 had GDM and 470 had normal glucose tolerance test as
the primary diagnosis. Some GDM risk factors were compared in two groups.
Results: Impaired glucose tolerance test was detected in 143 (23.3%) patients.
Prevalence of GDM was higher in the first-trimester fasting blood sugar (FBS) > 90
qmg/dl group (p < 0.001). Comparison of the GDM and the normal glucose tolerance
test groups demonstrated significant differences in maternal age, first-trimester FBS,
third-trimester vitamin D level, maternal platelet count, maternal body mass index
(BMI) (before 12 wk of gestation), weight gain during pregnancy, and the history of
gestational complications in previous pregnancy (p < 0.01). In logistic regression, GDM
was independently associated with older maternal age, higher first-trimester FBS,
the history of gestational complications in previous pregnancy, lower third-trimester
vitamin D level, and higher maternal platelet count (p < 0.01).
Conclusion: Both patients with higher initial FBS and the history of gestational
complications in previous pregnancy should be considered high risk for GDM and
screened earlier.
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1. Introduction
Gestational diabetes mellitus (GDM) is defined
as the glucose intolerance that is started or
diagnosed essentially during the pregnancy (1, 2).
The prevalence of GDM is variable depending on
the area of study, population, methods of data
collection, selection and diagnosis criteria, and
screening programs. This condition occurs in 1-14%
of all pregnancies in the United States. In Iran, the
prevalence of the disease varies from 1.3 to 18.8%
(3-5).
It leads to large for gestational age and
metabolic disorders in infants, and preeclampsia
and hypertension in mothers. Due to short-
and long-term healthcare implications from both
maternal and fetal concerns, GDM deserves proper
prevention, diagnosis, and management. Factors
that influence the rising prevalence of GDM include
increased maternal age at the time of conception,
sedentary life, obesity, and diabetes epidemics
(4, 6). It is well-known that early diagnosis and
management of women with risk of GDM, might
diminish maternal and neonatal morbidity (7, 8).
Although enquiring about the risk factors
associated with GDM is the cornerstone of any
clinical assessment, the specificity and sensitivity
of history for the diagnosis of GDM are very low and
insufficient, it would be appropriate to recommend
adding other factors for universal screening of
early GDM diagnosis (5).
A previous obstetric history is reported as
traditional and most often as a risk factor
for GDM (9). In addition, a previous history of
pregnancy complications including preeclampsia,
hypertension, intra uterus growth retardation
(IUGR), and GDM have common risk factors
consisting of increased maternal age, nulliparity,
multiple gestation pregnancies, and an increased
pre-pregnancy body mass index (BMI). vascular
endothelial dysfunction is considered to be the
underlying pathophysiology of these disorders (10).
Fasting plasma glucose (FPG) is convenient
to administer, nicely tolerated, affordable,
reliable, reproducible, and has been reported
to fluctuate very little during gestation. So, there
are certain advantages of its use as a screening
test for GDM than the glucose challenge test
(11). Notwithstanding the excessive incidence of
GDM in the far East population, few studies have
targeted at the predictive risk factors for GDM, and
records about factors related to GDM incidence is
confined. Additional studies are needed to validate
previous research on the factors associated with
GDM.
Consequently, this survey was designed to
investigate the risk factors associated with
developing GDM and specifically to assess
the significance of previous history of pregnancy
complications and fasting blood sugar (FBS) level
during first trimester to predict GDM.
2. Materials and Methods
This case-control study is a retrospective file
review of women who received prenatal care
at a prenatal clinic in Imam Khomeini Hospital,
Tehran, Iran. Accordingly, our survey population
was a high-risk group (because we had more
pregnant women with gestational diabetic, growth
retardation, hypertension and etc. than the normal
papulation). Patients’ medical records were utilized
to create reports of all women who received
prenatal care between March 2017 and March
2018. The inclusion criteria were: 1) maternal age
≥ 17 yr; 2) confirmed singleton pregnancy of < 16
wk gestation; and 3) planned to receive ongoing
prenatal care in our prenatal health center. On
the other hand, the exclusion criteria included: 1)
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twin or multifetal pregnancy; 2) maternal immune-
deficiency diseases; 3) women’s medical records
indicating impaired glucose tolerance test (GTT),
and/or pre-GDM; and 4) lack of data on the GTT,
first-trimester FPG level, antenatal visits, or child
delivery. In this survey, if the screening at the first
prenatal visit showed An FBS ≥ 126 mg/dl, the case
was also excluded.
At the first prenatal visit risk assessment was
performed for all pregnant women. High-risk
women for GDM (positive family history disease
[FHD], age > 35 yr, prepregnancy obesity, personal
previous history of GDM, previous macrosomia or
glycosuria) were screened as soon as possible.
High-risk women were retested at 24-28 wk if
negative at the first visit. Women who were not
at high risk for GDM at 24-28 wks’ gestation had
screening test by the three steps 75gr oral GTT (75
gr 2hOGTT) (3).
Patients underwent a 75 gr 2hOGTT after
an appropriate three-day carbohydrate load and
overnight fasting of at least 8 hr. Blood sugar (BS)
was measured in fasting, and at 1 and 2 hr after
the 75 gr oral glucose intake. GDM was diagnosed
based on International association of diabetes and
pregnancy study groups guidelines: any abnormal
value equal or greater than knowing threshold
values was considered GDM (FBS ≥ 92 mg/dl [5.1
mmol/L]; 1 hr BS ≥ 180 mg/dl [10.0 mmol/L)] 2 hr
BS ≥ 153 mg/dl [8.5 mmol/L]) (one-step strategy
according to American Diabetic Association) (12).
Moreover, serum glucose concentration was
measured by the glucose oxidase method in
an auto-analyzer (Roche Diagnostics). In the
GDM group, nutrition counseling for the initiation
of diabetic diet was conducted and a 2-wk
observation was planned. Then, FBS and (2 hr
post prandial BS) 2hppBS were checked. If FBS
≤ 92 mg/dl and 2hppBS ≤ 120 mg/dl, they were
classified as class A1 GDM and controlled by diet
and were followed by every 2 wk FBS and 2hppBS
checking. If FBS > 92 mg/dl and/or 2hppBS > 120
mg/dl, they were classified as class A2 GDM and
drug therapy (insulin or metformin) was considered
(13).
In total, 701 medical records were collected.
After review, 46 were excluded due to lack of
data on the GTT, antenatal visits, or child delivery.
Furthermore, 16 records with the diagnosis of type
1 or 2 diabetes and 26 records with pre-gestational
diabetes were excluded. Eventually, 613 patients
were included in the study of which 143 had
GDM and 470 had normal glucose tolerance test
(NGT) as the primary diagnosis. BMI (weight [kg]
/height [m2]) was measured at 12 wks’ gestation
or earlier in this pregnancy. Every included
participant had been asked about their use of
vitamin and mineral supplements at each prenatal
visit, and any multivitamin supplementation was
mentioned. Data on the type of hyperglycemia
control (nutrition, insulin, or metformin) were
collected. Women who did not have GDM until
the third trimester were followed-up monthly, after
which till delivery fortnightly. For the GDM group,
during the first and second trimesters antenatal
care involved fortnightly visits, then weekly in
the third trimester, if identified early. The GDM
group was advised to obey diabetic diet based on
nutrition counseling and exercise for at least 30min
three times weekly. They were under tight controls
of BS during their pregnancies (FBS≤ 92mg/dl and
2hppBS ≤ 120 mg/dl).
Trained midwives had collected data in
each prenatal visit and for all pregnant women
included in the study obtained anthropometric and
demographic data by an established questionnaire
form. At each visit, mother’s weight gain was
recorded. All eligible pregnant women replied to
a structured questionnaire about age, their past
obstetric history (e.g., preeclampsia, hypertension,
IUGR, preterm labor [PTL], Preterm premature
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rupture of the membranes [PPROM], placenta
abruption and GDM), family history of diabetes
in first degree relatives, parity and number
of pregnancies. Physical examinations of the
pregnant women were performed and arterial
blood pressure and weight were recorded. First-
and third-trimester laboratory data (FBS, thyroid
stimulating hormone [TSH], hemoglobin, platelet,
and Vitamin D) were obtained. The gestational age
of 12 wk was calculated through sonography.
Moreover, pregnant women were followed-up
until delivery for poor obstetric and neonatal
outcomes. Maternal weight gain in each trimester
during pregnancy and obstetric outcomes (gender
of newborn, birth weight, type of delivery
[caesarean section or normal vaginal delivery],
PTL, IUGR, preeclampsia, and PPROM) were
recorded.
The prevalence of GDM were compared
between the groups of first trimester FBS ≤ 90
mg/dl and FBS > 90. GDM and NGT mothers
were compared for the prevalence of different
factors including, maternal age, first-trimester FBS,
first and third-trimester vitamin D levels, maternal
platelet count, maternal BMI (before the 12th wk
of gestation), weight gain during the pregnancy,
nuchal translucency (NT), anemia, TSH, family
history of diabetes mellitus, infant sex and infant
weigh, prevalence of pregnancy complications
(namely, PTL, PROM, preeclampsia, and IUGR), and
the history of gestational complications in previous
pregnancies (e.g., preeclampsia, hypertension,
IUGR, PTL, placenta abruption, and GDM).
2.1. Ethical considerations
The study was approved by the ethics
committee of the Imam Khomeini Hospital, Tehran
University of Medical Sciences, Tehran, Iran (Code:
IR.TUMS.IKHC.RCE.1396.3435). A written informed
consent was obtained from all patients about their
anonymous and voluntary participation. They had
been additionally ensured that the results of the
study would be confidential and advantageous to
them or other pregnant women.
2.2. Statistical analysis
Data were analyzed using the version 18.0 of
SPSS for Windows (SPSS Inc., Chicago, Illinois,
USA). In determining the prevalence and mean
values descriptive statistical techniqueswere used.
To examine the correlation between the
variables the Pearson’s correlation test was
used. For analyzing the normally distributed data
the independent samples t test, Chi-square and
Fisher’s exact test, one-way analysis of variance,
and LSD were used.
The Q-Q plot for normality was used. With
a backward model, logistic regression analysis
was performed for related risk factors of GDM.
While GDM was taken as the dependent variable,
associated risk factors for GDM were considered
as independent variables, in this analysis. Using
the Mann-Whitney U and Kruskal-Wallis tests, non-
parametric data were analyzed.
For quantitative data and percentage of
qualitative data, results are shown as arithmetic
mean ± standard deviation. P < 0.05 was
considered as statistically significant. To compare
the means between groups, the paired samples t
test was used. In logistic regression analysis, odds
ratio (OR) (95% CI) was used (5).
3. Result
The mean age of the participants was 31.24 ±
4.78 yr (range 19-45 yr). The mean maternal, BMI
was 24.81 ± 4.01 kg/m2 (range 16.66-46.33 kg/m2).
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The characteristics of the study population are
outlined in Table I. After omitting the diabetic
patients and incomplete data, 613 participants
remained. An impaired GTT was detected in
143 (23.3%) patients. For BS controlling, 72
(11.7%) patients used insulin and/or metformin;
the remainder (71) were controlled by diet
modification.
Among the 613 women, 461 (75.2%) had a first-
trimester FBS ≤ 90 mg/dl and 152 (24.8%) had
FBS > 90. Of those with FBS ≤ 90 mg/dl, 83 (18%)
patients had impaired GTT and 38 (8.2%) used
insulin and/or metformin to control their BS.
Among those with FBS > 90 mg/dl, 60 (39.5%)
patients had impaired GTT and 34 (22.4%) used
insulin and/or metformin to control their BS. GDM
prevalence was higher in the first-trimester FBS >
90 mg/dl group (p < 0.001) (Table II).
A comparison of the GDM and the NGT
groups demonstrated significant differences in the
maternal age, first-trimester FBS, third-trimester
vitamin D levels, maternal platelet count, maternal
BMI (before the 12th wk of gestation), weight
gain during the pregnancy, and the history of
gestational complications in previous pregnancies
(Table III).
No association was seen between GDM and NT,
anemia, TSH, family history of diabetes mellitus,
infant sex, and infant weight.
The overall prevalence of pregnancy
complications (namely PTL, PROM, preeclampsia,
and IUGR) was not significantly different between
diabetic and non-diabetic patients (p = 0.530).
However, the history of gestational complications
in previous pregnancies (e.g., preeclampsia,
hypertension, IUGR, PTL, placenta abruption, and
GDM) was associated with a higher chance of GDM
in the current pregnancy (p = 0.004). A multivariate
analysis using a multiple logistic regression model
was perform to determine the independence of
these variables.
In this analysis, GDM was significantly and
independently associated with older maternal age,
higher first-trimester FBS, the history of gestational
complications in previous pregnancy, lower third-
trimester vitamin D level, and higher maternal
platelet count (p < 0.01). (Table IV). These risk
factors were independent predictors of GDM.
Table I. Characteristics of the study population
Variables Patients




Infant’s birth weight (gr)* 3278.26 ± 417.99 (1200–4480)
Infant’s gestational age at birth (wk) 38.33 (31–42)






Maternal BMI (kg/m2)* 24.81 ± 4.01 (16.66–46.33)
Weight gain during pregnancy (kg)* 14.69 ± 5.26 (1–37)
Impaired GTT*** 143 (23.3%)
*Data presented as Mean ± SD (mi-max), **Data presented as percentages, ***Data presented as n (%), Yr: Year, gr: Gram, wk:
Week, NVD: Normal vaginal delivery, BMI: Body mass index, kg/m2: kilogram/metere2, kg: Kilogram, GTT: Glucose tolerance
test
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Table II. Prevalence of GDM and drug-controlled GDM in Iranian pregnant women according to their first-trimester FBS levels
during their first trimester
FBS ≤ 90 FBS > 90 Total P-value
Having GDM or Not
Non-GDM 378 (80.9)/(82) 92 (19.1)/(60.5) 470 (76.7)
GDM 83 (57.9)/(18) 60 (42.1)/(39.5) 143 (23.3)
Total 461 (75.2)/(100) 152 (24.8)/(100) 613 (100)
< 0.001∗
Drug-controlled GDM
Non-drug use 423 (78.2)/(91.8) 118 (21.8)/(77.6) 541 (88.3)
Drug use 38 (52.8)/(8.2) 34 (47.2)/(22.4) 72 (11.7)
Total 461 (75.2)/(100) 152 (24.8)/(100) 613 (100)
< 0.001∗
Data presented as n (%). Pearson’s correlation test. *Significant difference between two groups, FBS: Fasting blood sugar, GDM:
Gestational diabetes mellitus
Table III. Clinical and metabolic characteristics of study groups
GDM* (n = 143) Non GDM* (n = 470) P-value
Maternal age (yr)* 32.62 ± 5.1 30.82 ± 4.61 < 0.001a
Maternal weight (before the 12th wk of gestation) [kg]* 67.59 ± 14.28 65.64 ± 10.43 0.078
Maternal BMI (before the 12th wk of gestation) [kg/m2 ]* 25.74 ± 4.73 24.53 ± 3.72 0.006a
FBS (1st trimester) [mg/dl]* 88.92 ± 11.9 83.77 ± 7.28 < 0.001a
TSH (1st trimester) [UI/dl]* 2.4 ± 0.7 2.35 ± 0.79 0.793
Vit D (1st trimester) [ng/dl]* 20.98 ± 16.04 20.99 ± 15.67 0.999
Hemoglobin (1st trimester) [mg/dl]* 13 ± 0.81 12.94 ± 1.24 0.597
Platelet count (1st trimester) [/𝜇l]* 259510.79 ± 52194.22 234164.44 ± 54438.74 < 0.001a
TSH (3rd trimester) [𝜇UI/dl]* 2.56 ± 0.59 2.28 ±0.22 0.097
Vit D (3rd trimester) [ng/dl]* 29.30 ± 12.22 33.75 ± 15.37 0.005a
Hemoglobin (3rd trimester) [mg/dl]* 12.17 ± 1.08 12.14 ± 1.32 0.881
Platelet count (3rd trimester) [/𝜇l]* 244290.91 ± 65190.17 215744.68 ± 56738.81 0.003a
Maternal weight gain during pregnancy [kg]* 12.48 ± 5.77 15.37 ± 4.91 < 0.001
Maternal weight gain (2nd trimester) [kg]* 5.76 ± 2.80 7.06 ± 2.78 < 0.001a
Maternal weight gain (3rd trimester) [kg]* 3.75 ± 1.36 5.41 ± 1.42 < 0.001a
Infant weight [gr]* 3288.19 ± 331.71 3275 ± 442.99 0.748
NT [mm]* 1.76 ± 0.61 1.68 ± 0.52 0.194
Past pregnancy obstetrical history [%]** 75 (52.4%) 182 (38.7%) 0.004a
Infant sex (male)*** 53% 58.9% 0.232
Delivery type (cesarean)*** 88.3% 87.2% 0.770
Overall prevalence of pregnancy complications** 16 (11.2%) 62 (13.2%) 0.530
Family history of diabetes mellitus** 64 (44.8%) 184 (39.1%) 0.244
*Data presented as Mean ± SD, **Data presented as percentages, ***Data presented as n (%). Pearson correlation test. P-value
was considered significant < 0.05, GDM: Gestational diabetes mellitus, BMI: Body mass index, FBS: Fasting blood sugar, TSH:
Thyroid stimulating hormone, Vit D: Vitamin D, NT: Nuchal translucency
Table IV. Logistic regression analysis of risk factors for GDM among 613 pregnant women
variable B SE Beta T P-value
Maternal age (yr) 0.02 0.007 0.23 3.071 0.002*
Maternal BMI (before the 12th week of gestation) [kg/m2 ] –0.008 0.007 –0.078 –1.115 0.267
FBS (1st trimester) [mg/dl] 0.009 0.003 0.202 2.755 0.007*
Platelet count (1st trimester) [/𝜇l] 0.000 –0.036 –0.428 0.669
Vit D (3rd trimester) [ng/dl] –0.006 0.002 –0.223 –3.220 0.002*
Platelet count (3rd trimester) [/𝜇l] 0.000 0.221 2.594 0.01*
Maternal weight gain during pregnancy [kg] –0.007 0.01 –0.099 –0.759 0.449
Maternal weight gain (during 2nd trimester) [kg] –0.012 0.015 –0.082 –0.824 0.411
Maternal weight gain (during 3rd trimester) [kg] –0.011 0.015 –0.071 –0.735 0.463
Past pregnancy obstetrical history [%] 0.103 0.057 0.124 1.81 0.027*
*P-value < 0.05 was considered as significant. logistic regression analysis, GDM: Gestational diabetes mellitus, BMI: Body mass
index, FBS: Fasting blood sugar, Vit D: Vitamin D
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4. Discussion
This research represents a population-based
study in which factors associated with GDM were
investigated. We found that higher FBS in the
first trimester, lower vitamin D level in the second
trimester, maternal age, maternal BMI (before the
12th wk of gestation), the history of gestational
complications in previous pregnancy, and weight
gain during the pregnancy were associated
with GDM. There were no association between
GDM and NT, anemia, status of thyroid function,
family history of diabetes mellitus, and neonate
weight. We found that the history of gestational
complications in the previous pregnancy, including
preeclampsia, hypertension, IUGR, PTL, placenta
abruption, and GDM, were associated with a
higher chance of GDM in the current pregnancy.
We also found a strong graded association
between fasting glucose level in the first trimester
and abnormal GTT; first-trimester higher FPG
levels among pregnant women constitutes an
independent risk factor for the development of
GDM. Maternal older age, higher first-trimester
FBS, lower third-trimester vitamin D level, the
history of gestational complications in previous
pregnancy, and higher maternal platelet count
were independent predictors of GDM.
GDM is a growing health challenge inmany parts
of the world. Certain populations are particularly
vulnerable to growing this circumstance due to
genetic, social, and environmental factors. Parallel
with increased incidence of obesity in adolescent
and adult women, gestational diabetes is detected
more frequently by obstetricians (14). GDM involves
serious, short- and long-term consequences
for both the neonate and the mom, including
macrosomia, caesarean section, birth trauma, a
predisposition to obesity, metabolic syndrome, and
diabetes mellitus later in life (15). Early prediction
of women at high risk for developing GDM is
likely to enhance pregnancy outcomes because
it can minimize later development of GDM or
its later maternal and perinatal complications by
applying effective intervention through diet and
exercise adjustment and medical therapies earlier
in pregnancy. Unfortunately, for early prediction of
GDM, there are no uniform worldwide indices (8).
In our study, 23.3% of patients had impaired
GTT known as GDM. Insulin and/or metformin
were needed to control diabetes in 11.7% of
patients, while in the remaining the disease
was controlled solely through diet and exercise
modification. Previous surveys have reported GDM
prevalence between 1 and 14% with extensive-
ranging variations among countries. Moreover,
within the identical area, the prevalence of GDM
varies on the subject of ethnicity, methods of data
collection, selection, the screening methods, and
the diagnostic criteria adopted (7, 9). Jafari-Shobeiri
and colleagues reported “the prevalence of GDM
in Iranian population to be 3.41% (the highest
and the lowest prevalence rates were 18.6%
and 1.3%, respectively)” (3). A higher incidence
in our study is probably because of relatively
higher-risk population attending to our tertiary
referral clinics. Also, as we use the newest
guideline (75g 2hOGTT) one-step strategy (Based
on the American Diabetic Association) (12) to
predict GDM, the prevalence is predictably higher.
In the Shahbazian and colleagues survey, the
prevalence of GDM was 29.9% among pregnant
women. The authors attributed their findings to
the application of newer guidelines (International
association of diabetes and pregnancy study
groups criteria) (4) which we believe is the case in
our study.
In our survey, the first-trimester fasting glucose
level was an independent predictor of GDM.
“higher first-trimester fasting glucose levels, within
the normoglycemic range were an independent
risk factor for the development of GDM in
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young pregnant women.” The use of FPG as
a GDM screening test offers some advantages
over the glucose challenge test because it is
easy to administer, nicely tolerated, affordable,
reliable, reproducible, and has been reported to
differ little during gestation. In order to avoid
GDM complications, first-trimester FBS would help
detect and treat seemingly healthy women with
GDM early in pregnancy (8, 11).
Based on the findings of our study, maternal age
is strongly associated with GDM. Therefore, the
older age of mother results in the greater chance
of GDM (9, 16-18).
In our study, the prevalence of GDM had a
positive association with maternal BMI and obesity.
Many surveys have reported that maternal BMI and
obesity are associated with a higher prevalence of
GDM and are independent risk factors for growing
GDM. Due to inappropriate lifestyle, the rate of
obesity is increasing which in turn follows by rising
rates of GDM (19-22).
Weight gain during pregnancy has been
associated with GDM in many previous surveys (7,
23-25). In our study, diabetic patients underwent
counseling by a nutritionist and adopted a strict
dietary and exercise regimen, and hence, we saw
a lower weight gain in GDM patients compared to
the non-GDM group in our study.
This shows the advantage of lifestyle
modification on at least some aspects of GDM
as expressed in the previous studies (25, 26).
In our study, despite tight glycemic control and
lower weight gain in diabetic mothers than in
non-diabetic mothers, neonatal birth weight was
not significantly different between them.
We found that third-trimester low vitamin D levels
were associatedwith increased risk of GDM. Similar
to our study, Burris et al showed “second-trimester
vitamin D levels were inversely associated with
glucose levels after 1-hr 50g glucose challenge
test” (27). A number of studies also showed a higher
prevalence of vitamin D deficiency in pregnancies
that complicated with GDM (28-30).
Further, a significant association was found
between higher platelet count and GDM. There
are several studies supporting this finding (31,
32). It might be attributed to the thrombosis
tendency in GDM. The association between GDM
and inflammationmight be another contribution (31,
32). In contrast to our study, Erikci and colleagues
showed that women with GDM had lower platelet
counts and higher mean platelet volume (MPV). It
might be due to relative small sample size in their
study (34 GDM and 45 normal pregnancies) (33).
We found no association between GDM and
TSH. Yang and coworkers reported that a low level
of FT4 is an independent risk factor for GDM;
however, TSH level and TPO antibody did not
predict GDM, in line with our findings (16).
In our study, patients with a history of a
previously complicated pregnancy, including
preeclampsia, hypertension, abortion, placental
abruption, PTL, IUGR, GDM, hypothyroidism,
and premature rupture of membranes, had a
greater risk of developing GDM. These previous
history of pregnancy complications have common
risk factors consisting of increased maternal
age, nulliparity, multiple gestation pregnancies,
and an increased prepregnancy BMI. Vascular
endothelial dysfunction is considered to be the
underlying pathophysiology of these conditions.
Although previous obstetric history has not yet
been considered a key risk factor for subsequent
development of GDM, it is imperative to clarify the
relationship of the two. Lee and colleagues found
that the risk of GDM in the second pregnancy was
further increased by preeclampsia and GDM in the
first pregnancy, which support our findings (10).
This finding suggests that patients with a positive
past gestational history should be considered as
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high risk for GDM and should be screened earlier
for GDM.
In this survey, because of close observation
and control of GDM patients, the prevalence of
pregnancy complications, including hypertension,
preeclampsia, intra uterus fetal death, and PTL was
not significantly different between the GDM and
non-GDM groups and were lower than previous
studies, which is best attributed to the early
diagnosis and management of diabetes in the
pregnancy.
It should be mentioned that this study has some
constraints. First, this is a retrospective study that
naturally depends on the medical records only.
Second, the status of participants before the 16th
wk of gestation was not considered in our study.
Third, this is a single-center study with relatively
small sample size. Further studies with larger
sample sizes and long-term follow-ups need to
be performed to verify our findings and focus on
gatheringmore information about the effectiveness
of early intervention for high-risk pregnant women
to prevent GDM incidence and its complications.
5. Conclusion
The aim of early GDM prediction is to identify
women at risk for adverse outcome of pregnancy
and improve the prognosis. The lack of consensus
concerning diagnostic criteria, however, made it
difficult for women with GDM to be identified
early. This survey provides information on early
GDM prediction to make local and evidence-based
decisions.
Patients with a history of previous complicated
pregnancy, including preeclampsia, abortion,
placental abruption, PTL, GDM, hypothyroidism,
IUGR, and premature rupture of membranes,
had a greater risk of developing GDM. This
finding suggests that patients with a positive past
gestational history should be considered high risk
for GDM and should be screened earlier for GDM.
This survey suggests women with higher fasting
first-trimester glucose levels which is in normal
range according to the oral glucose tolerance test
(OGTT) are at an increased risk of developing GDM
during pregnancy. Our study suggests that higher
initial FPG which is in normal level and the history
of gestational complications in previous pregnancy
could be used as an indicator for predicting the
development of GDM.
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